Parenteral Compounding Market Outlook (2023 to 2033)

The parenteral compounding market size is projected to be worth US$ 1.7 billion in 2023. The market is likely to surpass US$ 4.0 billion by 2033 at a CAGR of 9.1% during the forecast period. The market is influenced by factors such as regulatory compliance, patient needs, and industry collaborations, with the ultimate goal of providing safe and customized medications to patients requiring parenteral administration.

The parenteral compounding market serves a wide range of healthcare settings, including hospitals, clinics, long-term care facilities, and home healthcare. It involves compounding pharmacies, outsourcing facilities, and healthcare professionals specializing in sterile compounding. Moreover, the growing focus on quality control and patient safety drives the demand for specialized parenteral compounding services.

Other Drivers Propelling the Demand for Parenteral Compounding Market include:

  • Increasing demand for personalized medicine to drive the market. Parenteral compounding plays a crucial role in personalized medicine by allowing the preparation of customized dosage forms, strengths, and combinations of medications to meet individual patient requirements.
  • Veterinary treatment frequently necessitates customized prescriptions for animals of various kinds and sizes, which may want parenteral pharmaceuticals. Parenteral compounding allows for the creation of veterinary drugs in appropriate dose forms and intensities to meet the specific needs of animal patients.
  • Clinical research investigations sometimes necessitate the use of experimental drugs that are not commercially accessible. These experimental medications may be prepared in parenteral compounding facilities under strict quality control standards, assuring compliance with regulatory rules and ethical issues. This element is assisting market expansion.

Challenges for Companies /Manufacturers in the Parenteral Compounding Market:

  • Parenteral compounding is subject to stringent regulatory restrictions, such as adhering to compounding standards, following sterile processing norms, and complying with regulatory agencies such as the United States Food and Drug Administration (FDA) and state boards of pharmacy.
  • To guarantee the sterility of compounded drugs, compounding plants must use stringent aseptic techniques and have adequate cleanroom facilities, equipment, and processes. Contamination is a critical concern, as even minor mistakes in sterile compounding can have serious ramifications for patient safety.
  • The regulatory landscape for compounding is always changing, with new legislation, recommendations, and enforcement actions. Keeping up with these developments and ensuring compliance can be difficult for compounding facilities.

Opportunities in the Parenteral Compounding Market Industry:

  • Expansion into veterinary care provides unexplored prospects for parenteral compounding, which can diversify compounding facilities' client base and revenue streams.
  • Focusing on component sterilization earlier in the manufacturing process helps lower the manufacturing footprint in a parenteral packaging plant, which might be a valuable market opportunity.
  • Pharmaceutical businesses should prioritize selecting a partner that can deliver a unique manufacturing technique ready to satisfy these industry objectives.

Latest Trends in the Parenteral Compounding Market:

  • Compounded sterile preparations (CSPs) that may be provided outside of the hospital environment are in high demand due to the increased desire for home-based healthcare services, including infusion treatment.
  • The parenteral compounding environment is changing as a result of technology integration. Compounding software, robotic devices, and automated compounding systems are being used to simplify procedures, improve accuracy, and increase production.
  • The growing need for personalized treatment and specialized therapy is driving a huge increase in specialty compounding. Parenteral compounding facilities are concentrating on generating customized formulations to satisfy unique patient needs, such as biologics, hormone replacement therapy, and cancer drugs.
Attributes Details
Parenteral Compounding Market Size (2023) US$ 1.7 million
Parenteral Compounding Market Projected Size (2033) US$ 4.0 billion
Value CAGR (2023 to 2033) 9.1%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2012 to 2022 Parenteral Compounding Market Demand Outlook Compared to 2023 to 2033 Forecast

From 2012 to 2022, the global parenteral compounding market experienced a CAGR of 6.8%, reaching a market size of US$ 1.7 million in 2023.

From 2012 to 2022, the global parenteral compounding market industry witnessed steady growth due to the increased need for sterile medications. Parenteral compounding is crucial for preparing sterile medications, especially for patients who cannot take oral medications. Sterile compound involves the preparation of injectable drugs, intravenous solutions, and other sterile medications has been a significant driver for the growth of the parenteral compound market over the years.

Drug shortage have been a recurring issue in the pharmaceutical industry. During drug shortages, compounding pharmacies play a vital role in to meet patient needs. The ability of compounding pharmacies to fill the haps during drug shortages has contributed to the growth of the parenteral compounding market.

Future Forecast for Parenteral Compounding Market Industry:

Looking ahead, the global parenteral compounding market industry is expected to rise at a CAGR of 9.1% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 4.0 billion by 2033.

The parenteral compounding market industry is expected to continue its growth trajectory from 2023 to 2033 due to increasing demand for personalized medicines. Personalized medicine, which involves tailoring medical treatment to an individual’s specific needs, is gaining momentum. Parenteral compounding plays a crucial role in preparing customized medications to meet individual patient requirements. As personalized medicine continues to evolve, the demand for parenteral compounding services is expected to rise, driving the market

Comparative View of the Parenteral Compounding Market

Parenteral Compounding Market:

Attributes Parenteral Compounding Market
CAGR (2023 to 2033) 9.1%
Market Value (2033) US$ 4.0 Billion
Opportunity Expansion into veterinary care provides unexplored prospects for parenteral compounding, which can diversify compounding facilities' client base and revenue streams.
Key Trends Compounded sterile preparations (CSPs) that may be provided outside of the hospital environment are in high demand due to the increased desire for home-based healthcare services, including infusion treatment.

Pain Management Device Market:

Attributes Pain Management Device Market
CAGR (2023 to 2033) 9.0%
Market Value (2033) US$ 6.2 billion
Opportunity Increasing cases of diabetes, cancer, and mental disorders along with the increasing incidence of accidents will therefore continue to provide a strong opportunities to the market
Key Trends Growing concern regarding drug addiction and the side effects of pain management therapeutics are encouraging people to adopt pain management devices.

Injectable Drug Market:

Attributes Injectable Drug Market
CAGR (2023 to 2033) 5.8%
Market Value (2033) US$ 991.3 million
Opportunity The demand for injectable drugs is increasing as the need to provide better patient outcomes has been on the rise.
Key Trends Expansion of manufacturer’s portfolios by introducing new and technologically advanced products.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Country-Wise Insights

Parenteral Compounding Market to Surge in the United States Due to Increasing Demand for Personalized Medicine.

Country The United States
Market Size (US$ Billion) by End of Forecast Period (2033) US$ 1.8 billion
CAGR % 2023 to End of Forecast (2033) 7.8%

The parenteral compounding market industry in the United States is expected to reach a market size of US$ 1.8 billion by 2033, expanding at a CAGR of 7.8%. Due to the increasing demand for personalized medicine. The USA healthcare system places a significant emphasis on personalized medicine, aiming to provide tailored treatment options to individual patients. Parenteral compounding allows healthcare providers to customize medications based on patients' specific needs, such as dosage, formulation, and route of administration. The growing demand for personalized medicine drives the growth of the parenteral compounding market in the USA

Rising Demand for Parenteral Compounding Market is Due to the Advancements in Compounding Technology.

Country The United Kingdom
Market Size (US$ Billion) by End of Forecast Period (2033) US$ 122.1 million
CAGR % 2023 to End of Forecast (2033) 4.2%

The parenteral compounding market industry in the United Kingdom is expected to reach a market share of US$ 122.1 million, expanding at a CAGR of 4.2% during the forecast period. The United Kingdom market is projected to growth of the market due to the advancements in compounding technology. Technological advancements in compounding equipment and processes enhance the efficiency, accuracy, and safety of parenteral compounding. The UK market benefits from innovative compounding technologies, such as sterile compounding devices, automated compounding systems, and software solutions that streamline compounding processes. These advancements attract healthcare providers and compounding facilities to invest in modern compounding technologies, driving market growth.

Notable Growth Expected in China's Parenteral Compounding Market Due to Rising Chronic Disease Burden.

Country China
Market Size (US$ Billion) by End of Forecast Period (2033) US$ 95.3 million
CAGR % 2023 to End of Forecast (2033) 17.6%

The parenteral compounding market industry in China is anticipated to reach a market size of US$ 95.3 million, moving at a CAGR of 17.6% during the forecast period. The parenteral compounding market industry in China is expected to grow prominently due to the increasing prevalence of chronic diseases. China is witnessing an increasing prevalence of chronic diseases, including cardiovascular diseases, diabetes, respiratory diseases, and cancer. These conditions often require specialized treatment regimens, including parenteral medications. The growing patient population with chronic diseases fuels the demand for parenteral compounding services in China.

Growing Geriatric Population to Drive Market Growth in Japan

Country Japan
Market Size (US$ Billion) by End of Forecast Period (2033) US$ 230.7 million
CAGR % 2023 to End of Forecast (2033) 12.1%

The parenteral compounding market industry in Japan is estimated to reach a market size of US$ 230.7 million by 2033, thriving at a CAGR of 12.1%. The market in Japan is predicted to grow because of the growing geriatric population. Japan has a large aging population, which is more susceptible to chronic diseases and complex medication requirements. As older adults often face challenges in swallowing or require specialized dosing, parenteral compounding provides an effective solution for delivering medications. The expanding geriatric population contributes to the increased demand for compounded parenteral medications in the country.

Demand for Parenteral Compounding Market is Rising Due to Increasing Demand for Personalized Medicines.

Country South Korea
Market Size (US$ Billion) by End of Forecast Period (2033) US$ 12.3 million
CAGR % 2023 to End of Forecast (2033) 11.8%

The parenteral compounding market industry in South Korea is expected to reach a market size of US$ 12.3 million, expanding at a CAGR of 11.8% during the forecast period. There is a growing demand for personalized medicine in South Korea, with a focus on providing tailored treatment options to individual patients. Parenteral compounding allows healthcare providers to customize medications based on specific patient needs, such as dosage, formulation, and route of administration. The increasing demand for personalized medicine supports the growth of the parenteral compounding market.

Category-Wise Insights

Hormone Replacement Therapy to Dominate Parenteral Compounding Market Industry with 49.7% Market Share in 2022

The hormone replacement therapy (HRT) is dominating the parenteral compounding market industry with a market share of 49.7% in 2022. The growth in unmet demand for HRT in emerging nations, as well as greater knowledge of the treatment of hormone issues, drives pharmaceutical companies to continuously bring new cutting-edge drugs to the global market. Furthermore, the rise in menopause and diseases related with hormone deficiency in developed countries has encouraged manufacturers to produce new products, such as combination therapy solutions, in place of the long-acting parenteral pharmaceuticals that were previously administered on a daily basis.

Which Application Is Widely Adopted In the Market?

The adults to dominating the parenteral compounding market with the market share of 54.0% in 2022. Adults often have more complex medication regimens compared to children. They may require multiple medications, higher dosages, or specialized formulations that are not commercially available. Parenteral compounding allows healthcare providers to customize medications specifically tailored to the individual needs of adult patients.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

How Key Players Stay Competitive in the Parenteral Compounding Market Industry?

This sector is fiercely competitive, with many companies fighting for market dominance. To stay ahead of the competition in such a circumstance, essential players must employ smart techniques.

Key Strategies Used by the Participants

  • Product Development

To produce innovative goods that increase efficacy, dependability, and cost-effectiveness, businesses make significant investments in research and development. Product innovation enables companies to stand out from the competition while also meeting the shifting needs of their customers.

  • Strategic Alliances & Collaborations

Strategic alliances and partnerships with other businesses are regularly formed by major players in an industry to take advantage of each other's advantages and expand their market reach. Through such arrangements, businesses may also obtain access to new technologies and markets.

  • Expansion into Emerging Markets

The market for parenteral compounding is rising quickly in developing nations like China and India. To boost their presence in these regions, major companies are expanding their distribution networks and building regional manufacturing sites.

  • Acquisitions and mergers

Key companies in the parenteral compounding market routinely employ mergers and acquisitions to strengthen their market positions, broaden their product offerings, and enter new markets.

Key Players in the Parenteral Compounding Market Industry

  • Avella Specialty Pharmacy
  • McKesson Corporation
  • Victoria Compounding Pharmacy
  • Vertisis Custom Pharmacy
  • Smith Caldwell Drug Store
  • Sixth Avenue Medical Pharmacy
  • Cantrell Drug Company
  • Clinigen Group
  • Dougherty's Pharmacy
  • Fagron N.V.
  • Fresenius Kabi
  • Institutional Pharmacy Solutions
  • Lorraine's Pharmacy
  • Millers Pharmacy
  • Nephron Pharmaceuticals
  • Wells Pharmacy Network
  • RXQ Compounding Pharmacy
  • AmerisourceBergen Corporation
  • B. Braun Melsungen AG Company
  • Pentec Health

Key Developments in the Parenteral Compounding Market:

  • In Dec. 2022, the APEX Compounding System, a macro and micro compounder from B. Braun Medical Inc. (B. Braun), a pioneer in smart infusion treatment and safe, effective pharmaceutical solutions, was launched.
  • In Jan. 2022, Cyclic Olefin Copolymer syringe was introduced by Nephron Pharmaceuticals Corporation as part of their 503B Outsourcing Facility Operation. 8.4% sodium bicarbonate injection in a COC syringe will soon be available from the company. This tactic will allow the business to expand its product line for the compounding pharmacy sector.

Segmentation Analysis of the Parenteral Compounding Market

By Therapeutic Area:

  • Pain Management
  • Hormone Replacement Therapy
  • Others

By Application:

  • Adults
  • Pediatric
  • Geriatric
  • Veterinary

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa

Frequently Asked Questions

What is the Growth Potential of the Parenteral Compounding Market?

The growth potential of the market is 9.1% through 2033.

What Challenges the Market Growth?

Stringent regulatory oversight challenges in parenteral compounding.

What is the Historical Performance of the Market?

From 2012 to 2022, the market experienced a CAGR of 6.8%.

What is the Key Trend in the Market?

High demand for compounded sterile preparations (CSPs) is the key trend.

What is the Lucrative Opportunity of the Market?

Focusing on unique manufacturing techniques for industry goals is the key trend.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Value Added Insights

    4.1. Product Adoption / Usage Analysis

    4.2. Recent Product Approvals/Launches

    4.3. Regulatory Landscape

    4.4. PESTEL Analysis

    4.5. Porter’s Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global Healthcare Expenditure Outlook

        5.1.2. Global Medical Device Outlook

        5.1.3. Global Life Expectancy Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Key Player’s Historic Growth

        5.2.2. Growing Advancements in Drug Delivery

        5.2.3. Evolution of the Pharmaceutical Industry

        5.2.4. Rising Demand for Minimally Invasive Procedures

        5.2.5. Increasing Preference For Personalized Medicine

        5.2.6. Demand of Immediate Pain Relief

        5.2.7. Frequency of Product Approvals

    5.3. Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033

    6.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022

    6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

7. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Therapeutic Area

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Million) Analysis By Therapeutic Area, 2012 to 2022

    7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033

        7.3.1. Pain Management

        7.3.2. Hormone Replacement Therapy

        7.3.3. Others

    7.4. Market Attractiveness Analysis By Therapeutic Area

8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Application

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis By Application, 2012 to 2022

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        8.3.1. Adults

        8.3.2. Pediatric

        8.3.3. Geriatric

        8.3.4. Veterinary

    8.4. Market Attractiveness Analysis By Application

9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region

    9.1. Introduction

    9.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2022

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    10.1. Introduction

    10.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        10.3.1. By Country

            10.3.1.1. USA

            10.3.1.2. Canada

        10.3.2. By Therapeutic Area

        10.3.3. By Application

    10.4. Market Attractiveness Analysis

        10.4.1. By Country

        10.4.2. By Therapeutic Area

        10.4.3. By Application

    10.5. Country Level Analysis & Forecast

        10.5.1. USA Market Analysis

            10.5.1.1. .Introduction

            10.5.1.2. Market Analysis and Forecast by Market Taxonomy

                10.5.1.2.1. By Therapeutic Area

                10.5.1.2.2. By Application

        10.5.2. Canada Market Analysis

            10.5.2.1. Introduction

            10.5.2.2. Market Analysis and Forecast by Market Taxonomy

                10.5.2.2.1. By Therapeutic Area

                10.5.2.2.2. By Application

    10.6. Market Trends

    10.7. Key Market Participants - Intensity Mapping

    10.8. Drivers and Restraints - Impact Analysis

11. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    11.1. Introduction

    11.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        11.3.1. By Country

            11.3.1.1. Brazil

            11.3.1.2. Mexico

            11.3.1.3. Argentina

            11.3.1.4. Rest of Latin America

        11.3.2. By Therapeutic Area

        11.3.3. By Application

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Therapeutic Area

        11.4.3. By Application

    11.5. Country Level Analysis & Forecast

        11.5.1. Brazil Market Analysis

            11.5.1.1. .Introduction

            11.5.1.2. Market Analysis and Forecast by Market Taxonomy

                11.5.1.2.1. By Therapeutic Area

                11.5.1.2.2. By Application

        11.5.2. Mexico Market Analysis

            11.5.2.1. Introduction

            11.5.2.2. Market Analysis and Forecast by Market Taxonomy

                11.5.2.2.1. By Therapeutic Area

                11.5.2.2.2. By Application

        11.5.3. Argentina Market Analysis

            11.5.3.1. Introduction

            11.5.3.2. Market Analysis and Forecast by Market Taxonomy

                11.5.3.2.1. By Therapeutic Area

                11.5.3.2.2. By Application

    11.6. Market Trends

    11.7. Key Market Participants - Intensity Mapping

    11.8. Drivers and Restraints - Impact Analysis

12. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        12.3.1. By Country

            12.3.1.1. Germany

            12.3.1.2. France

            12.3.1.3. Italy

            12.3.1.4. UK

            12.3.1.5. Spain

            12.3.1.6. Russia

            12.3.1.7. BENELUX

            12.3.1.8. Rest of Europe

        12.3.2. By Therapeutic Area

        12.3.3. By Application

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Therapeutic Area

        12.4.3. By Application

    12.5. Country Level Analysis & Forecast

        12.5.1. Germany Market Analysis

            12.5.1.1. .Introduction

            12.5.1.2. Market Analysis and Forecast by Market Taxonomy

                12.5.1.2.1. By Therapeutic Area

                12.5.1.2.2. By Application

        12.5.2. France Market Analysis

            12.5.2.1. Introduction

            12.5.2.2. Market Analysis and Forecast by Market Taxonomy

                12.5.2.2.1. By Therapeutic Area

                12.5.2.2.2. By Application

        12.5.3. Italy Market Analysis

            12.5.3.1. Introduction

            12.5.3.2. Market Analysis and Forecast by Market Taxonomy

                12.5.3.2.1. By Therapeutic Area

                12.5.3.2.2. By Application

        12.5.4. UK Market Analysis

            12.5.4.1. .Introduction

            12.5.4.2. Market Analysis and Forecast by Market Taxonomy

                12.5.4.2.1. By Therapeutic Area

                12.5.4.2.2. By Application

        12.5.5. Spain Market Analysis

            12.5.5.1. .Introduction

            12.5.5.2. Market Analysis and Forecast by Market Taxonomy

                12.5.5.2.1. By Therapeutic Area

                12.5.5.2.2. By Application

        12.5.6. Russia Market Analysis

            12.5.6.1. .Introduction

            12.5.6.2. Market Analysis and Forecast by Market Taxonomy

                12.5.6.2.1. By Therapeutic Area

                12.5.6.2.2. By Application

        12.5.7. BENELUX Market Analysis

            12.5.7.1. .Introduction

            12.5.7.2. Market Analysis and Forecast by Market Taxonomy

                12.5.7.2.1. By Therapeutic Area

                12.5.7.2.2. By Application

    12.6. Market Trends

    12.7. Key Market Participants - Intensity Mapping

    12.8. Drivers and Restraints - Impact Analysis

13. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        13.3.1. By Country

            13.3.1.1. India

            13.3.1.2. Thailand

            13.3.1.3. Indonesia

            13.3.1.4. Malaysia

            13.3.1.5. Rest of South Asia

        13.3.2. By Therapeutic Area

        13.3.3. By Application

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Therapeutic Area

        13.4.3. By Application

    13.5. Country Level Analysis & Forecast

        13.5.1. India Market Analysis

            13.5.1.1. .Introduction

            13.5.1.2. Market Analysis and Forecast by Market Taxonomy

                13.5.1.2.1. By Therapeutic Area

                13.5.1.2.2. By Application

        13.5.2. Thailand Market Analysis

            13.5.2.1. .Introduction

            13.5.2.2. Market Analysis and Forecast by Market Taxonomy

                13.5.2.2.1. By Therapeutic Area

                13.5.2.2.2. By Application

        13.5.3. Indonesia Market Analysis

            13.5.3.1. Introduction

            13.5.3.2. Market Analysis and Forecast by Market Taxonomy

                13.5.3.2.1. By Therapeutic Area

                13.5.3.2.2. By Application

        13.5.4. Malaysia Market Analysis

            13.5.4.1. Introduction

            13.5.4.2. Market Analysis and Forecast by Market Taxonomy

                13.5.4.2.1. By Therapeutic Area

                13.5.4.2.2. By Application

    13.6. Market Trends

    13.7. Key Market Participants - Intensity Mapping

    13.8. Drivers and Restraints - Impact Analysis

14. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        14.3.1. By Country

            14.3.1.1. China

            14.3.1.2. Japan

            14.3.1.3. South Korea

        14.3.2. By Therapeutic Area

        14.3.3. By Application

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Therapeutic Area

        14.4.3. By Application

    14.5. Country Level Analysis & Forecast

        14.5.1. China Market Analysis

            14.5.1.1. .Introduction

            14.5.1.2. Market Analysis and Forecast by Market Taxonomy

                14.5.1.2.1. By Therapeutic Area

                14.5.1.2.2. By Application

        14.5.2. Japan Market Analysis

            14.5.2.1. Introduction

            14.5.2.2. Market Analysis and Forecast by Market Taxonomy

                14.5.2.2.1. By Therapeutic Area

                14.5.2.2.2. By Application

        14.5.3. South Korea Market Analysis

            14.5.3.1. Introduction

            14.5.3.2. Market Analysis and Forecast by Market Taxonomy

                14.5.3.2.1. By Therapeutic Area

                14.5.3.2.2. By Application

    14.6. Market Trends

    14.7. Key Market Participants - Intensity Mapping

    14.8. Drivers and Restraints - Impact Analysis

15. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        15.3.1. By Country

            15.3.1.1. Australia

            15.3.1.2. New Zealand

        15.3.2. By Therapeutic Area

        15.3.3. By Application

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Therapeutic Area

        15.4.3. By Application

    15.5. Country Level Analysis & Forecast

        15.5.1. Australia Market Analysis

            15.5.1.1. .Introduction

            15.5.1.2. Market Analysis and Forecast by Market Taxonomy

                15.5.1.2.1. By Therapeutic Area

                15.5.1.2.2. By Application

        15.5.2. New Zealand Market Analysis

            15.5.2.1. Introduction

            15.5.2.2. Market Analysis and Forecast by Market Taxonomy

                15.5.2.2.1. By Therapeutic Area

                15.5.2.2.2. By Application

    15.6. Market Trends

    15.7. Key Market Participants - Intensity Mapping

    15.8. Drivers and Restraints - Impact Analysis

16. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        16.3.1. By Country

            16.3.1.1. GCC Countries

            16.3.1.2. Türkiye

            16.3.1.3. Northern Africa

            16.3.1.4. South Africa

            16.3.1.5. Rest of Middle East and Africa

        16.3.2. By Therapeutic Area

        16.3.3. By Application

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Therapeutic Area

        16.4.3. By Application

    16.5. Country Level Analysis & Forecast

        16.5.1. GCC Countries Market Analysis

            16.5.1.1. .Introduction

            16.5.1.2. Market Analysis and Forecast by Market Taxonomy

                16.5.1.2.1. By Therapeutic Area

                16.5.1.2.2. By Application

        16.5.2. Türkiye Market Analysis

            16.5.2.1. Introduction

            16.5.2.2. Market Analysis and Forecast by Market Taxonomy

                16.5.2.2.1. By Therapeutic Area

                16.5.2.2.2. By Application

        16.5.3. Northern Africa Market Analysis

            16.5.3.1. Introduction

            16.5.3.2. Market Analysis and Forecast by Market Taxonomy

                16.5.3.2.1. By Therapeutic Area

                16.5.3.2.2. By Application

        16.5.4. South Africa Market Analysis

            16.5.4.1. Introduction

            16.5.4.2. Market Analysis and Forecast by Market Taxonomy

                16.5.4.2.1. By Therapeutic Area

                16.5.4.2.2. By Application

    16.6. Market Trends

    16.7. Key Market Participants - Intensity Mapping

    16.8. Drivers and Restraints - Impact Analysis

17. Market Structure Analysis

    17.1. Market Analysis by Tier of Companies

    17.2. Market Share Analysis of Top Players

    17.3. Market Presence Analysis

18. Competition Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Competition Deep Dive

        18.3.1. Avella Specialty Pharmacy

            18.3.1.1. Overview

            18.3.1.2. Product Portfolio

            18.3.1.3. Key Financials

            18.3.1.4. Sales Footprint

            18.3.1.5. SWOT Analysis

            18.3.1.6. Strategy Overview

                18.3.1.6.1. Marketing Strategy

                18.3.1.6.2. Product Strategy

                18.3.1.6.3. Channel Strategy

        18.3.2. McKesson Corporation

            18.3.2.1. Overview

            18.3.2.2. Product Portfolio

            18.3.2.3. Key Financials

            18.3.2.4. Sales Footprint

            18.3.2.5. SWOT Analysis

            18.3.2.6. Strategy Overview

                18.3.2.6.1. Marketing Strategy

                18.3.2.6.2. Product Strategy

                18.3.2.6.3. Channel Strategy

        18.3.3. Victoria Compounding Pharmacy

            18.3.3.1. Overview

            18.3.3.2. Product Portfolio

            18.3.3.3. Key Financials

            18.3.3.4. Sales Footprint

            18.3.3.5. SWOT Analysis

            18.3.3.6. Strategy Overview

                18.3.3.6.1. Marketing Strategy

                18.3.3.6.2. Product Strategy

                18.3.3.6.3. Channel Strategy

        18.3.4. Vertisis Custom Pharmacy

            18.3.4.1. Overview

            18.3.4.2. Product Portfolio

            18.3.4.3. Key Financials

            18.3.4.4. Sales Footprint

            18.3.4.5. SWOT Analysis

            18.3.4.6. Strategy Overview

                18.3.4.6.1. Marketing Strategy

                18.3.4.6.2. Product Strategy

                18.3.4.6.3. Channel Strategy

        18.3.5. Smith Caldwell Drug Store

            18.3.5.1. Overview

            18.3.5.2. Product Portfolio

            18.3.5.3. Key Financials

            18.3.5.4. Sales Footprint

            18.3.5.5. SWOT Analysis

            18.3.5.6. Strategy Overview

                18.3.5.6.1. Marketing Strategy

                18.3.5.6.2. Product Strategy

                18.3.5.6.3. Channel Strategy

        18.3.6. Sixth Avenue Medical Pharmacy

            18.3.6.1. Overview

            18.3.6.2. Product Portfolio

            18.3.6.3. Key Financials

            18.3.6.4. Sales Footprint

            18.3.6.5. SWOT Analysis

            18.3.6.6. Strategy Overview

                18.3.6.6.1. Marketing Strategy

                18.3.6.6.2. Product Strategy

                18.3.6.6.3. Channel Strategy

        18.3.7. Cantrell Drug Company

            18.3.7.1. Overview

            18.3.7.2. Product Portfolio

            18.3.7.3. Key Financials

            18.3.7.4. Sales Footprint

            18.3.7.5. SWOT Analysis

            18.3.7.6. Strategy Overview

                18.3.7.6.1. Marketing Strategy

                18.3.7.6.2. Product Strategy

                18.3.7.6.3. Channel Strategy

        18.3.8. Clinigen Group

            18.3.8.1. Overview

            18.3.8.2. Product Portfolio

            18.3.8.3. Key Financials

            18.3.8.4. Sales Footprint

            18.3.8.5. SWOT Analysis

            18.3.8.6. Strategy Overview

                18.3.8.6.1. Marketing Strategy

                18.3.8.6.2. Product Strategy

                18.3.8.6.3. Channel Strategy

        18.3.9. Dougherty's Pharmacy

            18.3.9.1. Overview

            18.3.9.2. Product Portfolio

            18.3.9.3. Key Financials

            18.3.9.4. Sales Footprint

            18.3.9.5. SWOT Analysis

            18.3.9.6. Strategy Overview

                18.3.9.6.1. Marketing Strategy

                18.3.9.6.2. Product Strategy

                18.3.9.6.3. Channel Strategy

        18.3.10. Fagron N.V.

            18.3.10.1. Overview

            18.3.10.2. Product Portfolio

            18.3.10.3. Key Financials

            18.3.10.4. Sales Footprint

            18.3.10.5. SWOT Analysis

            18.3.10.6. Strategy Overview

                18.3.10.6.1. Marketing Strategy

                18.3.10.6.2. Product Strategy

                18.3.10.6.3. Channel Strategy

        18.3.11. Fresenius Kabi

            18.3.11.1. Overview

            18.3.11.2. Product Portfolio

            18.3.11.3. Key Financials

            18.3.11.4. Sales Footprint

            18.3.11.5. SWOT Analysis

            18.3.11.6. Strategy Overview

                18.3.11.6.1. Marketing Strategy

                18.3.11.6.2. Product Strategy

                18.3.11.6.3. Channel Strategy

        18.3.12. Institutional Pharmacy Solutions

            18.3.12.1. Overview

            18.3.12.2. Product Portfolio

            18.3.12.3. Key Financials

            18.3.12.4. Sales Footprint

            18.3.12.5. SWOT Analysis

            18.3.12.6. Strategy Overview

                18.3.12.6.1. Marketing Strategy

                18.3.12.6.2. Product Strategy

                18.3.12.6.3. Channel Strategy

        18.3.13. Lorraine's Pharmacy

            18.3.13.1. Overview

            18.3.13.2. Product Portfolio

            18.3.13.3. Key Financials

            18.3.13.4. Sales Footprint

            18.3.13.5. SWOT Analysis

            18.3.13.6. Strategy Overview

                18.3.13.6.1. Marketing Strategy

                18.3.13.6.2. Product Strategy

                18.3.13.6.3. Channel Strategy

        18.3.14. Millers Pharmacy

            18.3.14.1. Overview

            18.3.14.2. Product Portfolio

            18.3.14.3. Key Financials

            18.3.14.4. Sales Footprint

            18.3.14.5. SWOT Analysis

            18.3.14.6. Strategy Overview

                18.3.14.6.1. Marketing Strategy

                18.3.14.6.2. Product Strategy

                18.3.14.6.3. Channel Strategy

        18.3.15. Nephron Pharmaceuticals

            18.3.15.1. Overview

            18.3.15.2. Product Portfolio

            18.3.15.3. Key Financials

            18.3.15.4. Sales Footprint

            18.3.15.5. SWOT Analysis

            18.3.15.6. Strategy Overview

                18.3.15.6.1. Marketing Strategy

                18.3.15.6.2. Product Strategy

                18.3.15.6.3. Channel Strategy

        18.3.16. Wells Pharmacy Network

            18.3.16.1. Overview

            18.3.16.2. Product Portfolio

            18.3.16.3. Key Financials

            18.3.16.4. Sales Footprint

            18.3.16.5. SWOT Analysis

            18.3.16.6. Strategy Overview

                18.3.16.6.1. Marketing Strategy

                18.3.16.6.2. Product Strategy

                18.3.16.6.3. Channel Strategy

        18.3.17. RXQ Compounding Pharmacy

            18.3.17.1. Overview

            18.3.17.2. Product Portfolio

            18.3.17.3. Key Financials

            18.3.17.4. Sales Footprint

            18.3.17.5. SWOT Analysis

            18.3.17.6. Strategy Overview

                18.3.17.6.1. Marketing Strategy

                18.3.17.6.2. Product Strategy

                18.3.17.6.3. Channel Strategy

        18.3.18. AmerisourceBergen Corporation

            18.3.18.1. Overview

            18.3.18.2. Product Portfolio

            18.3.18.3. Key Financials

            18.3.18.4. Sales Footprint

            18.3.18.5. SWOT Analysis

            18.3.18.6. Strategy Overview

                18.3.18.6.1. Marketing Strategy

                18.3.18.6.2. Product Strategy

                18.3.18.6.3. Channel Strategy

        18.3.19. B. Braun Melsungen AG Company

            18.3.19.1. Overview

            18.3.19.2. Product Portfolio

            18.3.19.3. Key Financials

            18.3.19.4. Sales Footprint

            18.3.19.5. SWOT Analysis

            18.3.19.6. Strategy Overview

                18.3.19.6.1. Marketing Strategy

                18.3.19.6.2. Product Strategy

                18.3.19.6.3. Channel Strategy

        18.3.20. Pentec Health

            18.3.20.1. Overview

            18.3.20.2. Product Portfolio

            18.3.20.3. Key Financials

            18.3.20.4. Sales Footprint

            18.3.20.5. SWOT Analysis

            18.3.20.6. Strategy Overview

                18.3.20.6.1. Marketing Strategy

                18.3.20.6.2. Product Strategy

                18.3.20.6.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

Explore Healthcare Insights

View Reports
Future Market Insights

Parenteral Compounding Market